Gsk (GSK) Gains from Investment Securities (2009 - 2026)

Gsk's Gains from Investment Securities history runs 18 years deep, the most recent figure standing at $33.5 million for Q2 2026.

• In Q2 2026, Gains from Investment Securities changed N/A year-over-year to $33.5 million; the TTM figure through Jun 2026 stood at $687.0 million (changed N/A YoY), while the FY2025 annual figure was $26.4 million, up 28.93% from the prior year.
• Gains from Investment Securities for Q2 2026 stood at $33.5 million, down from $195.5 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $446.9 million in Q4 2022, with the low at $19.0 million in Q1 2024.
• The 5-year median for Gains from Investment Securities is $195.5 million (2026), against an average of $203.2 million.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities plunged 88.14% in 2024, then jumped 614.88% in 2025.
• Gsk's Gains from Investment Securities stood at $446.9 million in 2022, then sank by 44.18% to $249.5 million in 2023, then plunged by 92.37% to $19.0 million in 2024, then soared by 1591.74% to $321.9 million in 2025, then plunged by 89.58% to $33.5 million in 2026.
• Business Quant data shows GSK's Gains from Investment Securities at $33.5 million in Q2 2026, $195.5 million in Q1 2026, and $321.9 million in Q4 2025.